CMS Policy Threatens Access to Home Infusion, Undermines Congressional Intent

THE VALUE OF HOME INFUSION

Home infusion is a cost-effective, convenient, and accessible alternative for patients to receive infused medications when other settings are impractical or unavailable, when transport outside the home is a burden, or when home administration can improve quality of life. Patients with serious infections, cancer, heart failure, immune system diseases, and other conditions can receive treatment at home, where they are comfortable and can resume their personal and professional activities.

Home Infusion Professional Services

- Infusion Therapy Assessment
- Plan of Care Development
- Care Coordination
- Drug Compounding
- Nursing

Issue Background

Historically, Medicare Part B infusion drugs were reimbursed at the Average Wholesale Price (AWP) with the expectation that the difference would be sufficient to offset the cost of extensive professional pharmacy services needed to administer the drugs.

Congress included provisions in the 21st Century Cures Act and the Bipartisan Budget Act of 2018 to lower the drug reimbursement rate from AWP to the Average Sales Price (ASP), while also requiring CMS to create a professional services benefit for Medicare Part B home infusion drugs, similar to benefits provided by Medicare Advantage and commercial plans.

In 2018, CMS undermined the policy created by Congress by issuing restrictive regulations that limit reimbursement to days when a nurse is physically present in the patient’s home, rather than each day the drug is infused.

<table>
<thead>
<tr>
<th></th>
<th>Before 2017</th>
<th>21st Century Cures + BBA</th>
<th>CMS Implementation</th>
<th>Most Commercial Payers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drugs</td>
<td>95% of AWP</td>
<td>ASN+6%</td>
<td>ASN+6%</td>
<td>A percentage of AWP</td>
</tr>
<tr>
<td>Nursing Services</td>
<td>every day</td>
<td>every day</td>
<td>only when nurse</td>
<td>reimbursed separately</td>
</tr>
<tr>
<td>Pharmacy Services</td>
<td>every day</td>
<td>every day</td>
<td>every day</td>
<td>every day</td>
</tr>
</tbody>
</table>
CONGRESSIONAL INTENT

In creating the home infusion professional services benefit for Part B infusion drugs, Congress intended to cover both pharmacy and nursing professional services and specified that providers would be reimbursed for each “infusion drug administration calendar day.” Congress intended for this new benefit to be billed with the existing supplies and drug codes for each day a drug was infused in the home.

Since then, bipartisan congressional leaders have reaffirmed that CMS’ requirement that a professional be present in the home “contradicts our intent in drafting and enacting this legislation and makes the reimbursement required by the bill inadequate.”

“To remain true to both the legislation and our intent, CMS should withdraw the requirement that a nurse or other professional be physically present “in the home” for reimbursement to occur, and instead recognize that reimbursement be made for each day that a home infusion drug is infused.”

Impact on Access

Reducing Patients’ Quality of Life
- Patient satisfaction for home infusion is extremely high.
- Most patients prefer to receive their infusions in the comfort of their own homes.
- Home infusion is particularly important for patients in rural areas.

No Reimbursement for Pharmacy Services
- Home infusion would be impossible without the expertise of a licensed pharmacist.
- Pharmacists handle the therapy assessment, plan of care development, care coordination, and drug compounding.
- Current CMS policy only recognizes care provided in a patient’s home.

Shifting to More Costly and Risky Settings
- CMS’ interpretation will shift patients to more expensive settings like hospitals and skilled nursing facilities.
- Hospital-based care puts patients at risk for hospital-acquired infections.

Setting a Dangerous Precedent
- Commercial payers seeking to replicate CMS’ approach might believe that “if it’s good enough for Medicare, it’s good enough for us.”
- This practice would quickly undermine home infusion access in the private market, threatening access for all home infusion patients.